-
胃癌是全世界较常见的恶性肿瘤,位居世界范围内因肿瘤相关致死疾病的第二位,每年约70万人死于胃癌[1]。18F-FDG PET/CT作为一项非侵入性检查方法被广泛用于恶性肿瘤的诊断、分期、化疗反应的评估和术后复发的检测[2-3]。近年来,随着显像技术的提高与治疗手段的不断更新,18F-FDG PET/CT在胃癌中的应用越发广泛。本文旨在就18F-FDG PET/CT在胃癌分期、复发及预后评估中的新趋势进行综述,以为临床医师提供最新的参考材料。
18F-FDG PET/CT在胃癌分期、复发检测及预后评估中的应用价值
Progress in research on the use of 18F-FDG PET/CT in the staging, recurrence detection, and prognosis evaluation of patients with gastric carcinoma
-
摘要: 胃癌是最常见的消化道恶性肿瘤。18F-FDG PET/CT作为一项集正电子发射断层扫描与计算机断层扫描于一体的成像模式,被广泛地应用于胃癌的诊断、分期、复发、疗效的评估及生存预后。笔者就18F-FDG PET/CT在胃癌的分期、复发及预后中的价值进行综述,以了解18F-FDG PET/CT在胃癌临床应用中的新进展。
-
关键词:
- 胃肿瘤 /
- 正电子发射断层显像计算机体层摄影术 /
- 氟脱氧葡萄糖F18
Abstract: Gastric cancer is the most common malignancy of the digestive tract worldwide.18F-FDG PET/CT is a novel imaging technique that combines the functional data of PET with the morphological information of CT. It is widely used in the diagnosis and staging of patients with gastric cancer. It is also used to evaluate the recurrence rates, chemotherapy response, and prognosis of patients with gastric cancer. To understand new trends in the clinical application of 18F-FDG PET/CT in gastric cancer, this article provides a review of the value of 18F-FDG PET/CT in the staging and evaluation of the recurrence and prognosis of gastric cancer. -
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA:Cancer J Clin, 2015, 65(2):87-108. doi: 10.3322/caac.21262 [2] Sun XP, Dong X, Lin L, et al. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer[J]. FEBS J, 2014, 281(1):115-128. DOI:10.1111/febs.12577. [3] Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer:Evidence from Studies on More Than 2300 Patients[J]. J Nucl Med, 2016, 57(3):420-430. DOI:10.2967/jnumed.115.158808. [4] Wu CX, Zhu ZH. Diagnosis and evaluation of gastric cancer by positron emission tomography[J]. World J Gastroenterol, 2014, 20(16):4574-4585. DOI:10.3748/wjg.v20.i16.4574. [5] Smyth E, Schöder H, Strong VE, et al. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer[J]. Cancer, 2012, 118(22):5481-5488. DOI:10.1002/cncr.27550. [6] Yun M. Imaging of Gastric Cancer Metabolism Using 18F-FDG PET/CT[J]. J Gastric Cancer, 2014, 14(1):1-6. DOI:10.5230/jgc. 2014. 14.1.1. [7] Redondo-Cerezo E, Martínez-Cara JG, Jiménez-Rosales R, et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series[J]. United European Gastroenterol J, 2017, 5(5):641-647. DOI:10.1177/2050640616684697. [8] Altini C, Niccoli AA, Di PA, et al. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography[J/OL]. Medicine (Baltimore), 2015, 94(20): e864[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/25997066. DOI: 10.1097/MD.0000000000000864. [9] Ma Q, Xin J, Zhao Z, et al. Value of 18F-FDG PET/CT in the diagnosis of primary gastric cancer via stomach distension[J/OL]. Eur J Radiol, 2013, 82(6): e302-306[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/23434453. DOI: 10.1016/j.ejrad.2013.01.021. [10] Youn SH, Seo KW, Lee SH, et al. 18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography:Computed Tomography for Preoperative Staging in Gastric Cancer Patients[J]. J Gastric Cancer, 2012, 12(3):179-186. DOI:10.5230/jgc.2012.12.3.179. [11] Minamimoto R, Senda M, Jinnouchi S, et al. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer:results from a nationwide Japanese survey[J]. Jpn J Radiol, 2014, 32(5):253-259. DOI:10.1007/s11604-014-0294-0. [12] Inoue K, Goto R, Okada K, et al. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity[J]. Ann Nucl Med, 2009, 23(7):643-649. DOI:10.1007/s12149-009-0286-9. [13] Lee SJ, Lee WW, Yoon HJ, et al. Regional PET/CT after water gastric inflation for evaluating loco-regional disease of gastric cancer[J]. Eur J Radiol, 2013, 82(6):935-942. DOI:10.1016/j.ejrad.2013.01.014. [14] Kim SJ, Cho YS, Moon SH, et al. Primary Tumor 18F-FDG Avidity Affects the Performance of 18F-FDG PET/CT for Detecting Gastric Cancer Recurrence[J]. J Nucl Med, 2016, 57(4):544-550. DOI:10.2967/jnumed.115.163295. [15] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA:Cancer J Clin, 2011, 61(2):69-90. doi: 10.3322/caac.v61:2 [16] Na SJ, o JH, Park JM, et al. Prognostic value of metabolic parameters on preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stageⅢ gastric cancer[J]. Oncotarget, 2016, 7(39):63968-63980. DOI:10.18632/oncotarget.11574. [17] Kaneko Y, Murray WK, Link E, et al. Improving patient selection for 18F-FDG PET scanning in the staging of gastric cancer[J]. J Nucl Med, 2015, 56(4):523-529. DOI:10.2967/jnumed.114.150946. [18] Ha TK, Choi YY, Song SY, et al. F18-fluorodeoxyglucose-positron emission tomography and computed tomography is not accurate in preoperative staging of gastric cancer[J]. J Korean Surg Soc, 2011, 81(2):104-110. DOI:10.4174/jkss.2011.81.2.104. [19] Yoon NR, Park JM, Jung HS, et al.[Usefulness of 18F-fluoro-2-deoxyglucose positron emission tomography in evaluation of gastric cancer stage] [J]. Korean J Gastroenterol, 2012, 59(5):347-353. doi: 10.4166/kjg.2012.59.5.347 [20] Stabile IAA, Telegrafo M, Lucarelli NM, et al. Comparison between CT Net enhancement and PET/CT SUV for N staging of gastric cancer: A case series[J/OL]. Ann Med Surg (Lond), 2017, 21: 1-6[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519227. DOI: 10.1016/j.amsu.2017.07.033. [21] Choi JI, Joo I, Lee JM. State-of-the-art preoperative staging of gastric cancer by MDCT and magnetic resonance imaging[J]. World J Gastroenterol, 2014, 20(16):4546-4557. DOI:10.3748/wjg.v20.i16. 4546. [22] Okumura Y, Aikou S, Onoyama H, et al. Evaluation of 18F-FDG uptake for detecting lymph node metastasis of gastric cancer: a prospective pilot study for one-to-one comparison of radiation dose and pathological findings[J/OL]. World J Surg Oncol, 2015, 13: 327[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4667411. DOI: 10.1186/s12957-015-0743-y. [23] Oh HH, Lee SE, Choi IS, et al. The peak-standardized uptake value (P-SUV) by preoperative positron emission tomography-computed tomography (PET-CT) is a useful indicator of lymph node metastasis in gastric cancer[J]. J Surg Oncol, 2011, 104(5):530-533. DOI:10.1002/jso.21985. [24] Wang Z, Chen JQ. Imaging in assessing hepatic and peritoneal metastases of gastric cancer:a systematic review[J]. BMC Gastroenterol, 2011, 11:19. DOI:10.1186/1471-230X-11-19. [25] Kawanaka Y, Kitajima K, Fukushima K, et al. Added value of pretreatment 18F-FDG PET/CT for staging of advanced gastric cancer:Comparison with contrast-enhanced MDCT[J]. Eur J Radiol, 2016, 85(5):989-995. DOI:10.1016/j.ejrad.2016.03.003. [26] Choi JY, Shim KN, Kim SE, et al. The clinical value of 18F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography for predicting regional lymph node metastasis and non-curative surgery in primary gastric carcinoma[J]. Korean J Gastroenterol, 2014, 64(6):340-347. doi: 10.4166/kjg.2014.64.6.340 [27] Kim DW, Park SA, Kim CG. Detecting the recurrence of gastric cancer after curative resection:comparison of FDG PET/CT and contrast-enhanced abdominal CT[J]. J Korean Med Sci, 2011, 26(7):875-880. DOI:10.3346/jkms.2011.26.7.875. [28] Ma DW, Kim JH, Jeon TJ, et al. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for the evaluation of bone metastasis in patients with gastric cancer[J]. Dig Liver Dis, 2013, 45(9):769-775. DOI:10.1016/j.dld.2013.02.009. [29] Lee JH, Son SY, Lee CM, et al. Factors predicting peritoneal recurrence in advanced gastric cancer:implication for adjuvant intraperitoneal chemotherapy[J]. Gastric Cancer, 2014, 17(3):529-536. DOI:10.1007/s10120-013-0306-2. [30] Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5934-5940. DOI:10.3748/wjg.v21.i19. 5934. [31] Lee JW, Lee SM, Son MW, et al. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2016, 43(5):881-888. DOI:10.1007/s00259-015-3249-5. [32] Wu LM, Hu JN, Hua J, et al. 18F-fluorodeoxyglucose positron emission tomography to evaluate recurrent gastric cancer:a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2012, 27(3):472-480. DOI:10.1111/j.1440-1746.2011.06919.x. [33] Lee JW, Lee SM, Lee MS, et al. Role of 18F-FDG PET/CT in the prediction of gastric cancer recurrence after curative surgical resection[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9):1425-1434. DOI:10.1007/s00259-012-2164-2. [34] Sharma P, Singh H, Suman SK, et al. 18F-FDG PET-CT for detecting recurrent gastric adenocarcinoma:results from a Non-Oriental Asian population[J]. Nucl Med Commun, 2012, 33(9):960-966. DOI:10.1097/MNM.0b013e328355b694. [35] Zou H, Zhao Y. 18FDG PET-CT for detecting gastric cancer recurrence after surgical resection:a meta-analysis[J]. Surg Oncol, 2013, 22(3):162-166. DOI:10.1016/j.suronc.2013.05.001. [36] Lee DY, Lee CH, Seo MJ, et al. Performance of 18F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients[J]. Ann Nucl Med, 2014, 28(8):789-795. DOI:10.1007/s12149-014-0871-4. [37] Choi BW, Zeon SK, Kim SH, et al. Significance of SUV on Follow-up 18F FDG PET at the Anastomotic Site of Gastroduodenostomy after Distal Subtotal Gastrectomy in Patients with Gastric Cancer[J]. Nucl Med Mol Imaging, 2011, 45(4):285-290. DOI:10.1007/s13139-011-0105-9. [38] Karimi P, Islami F, Anandasabapathy S, et al. Gastric cancer:descriptive epidemiology, risk factors, screening, and prevention[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23(5):700-713. DOI:10.1158/1055-9965.EPI-13-1057. [39] Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer:current status of diagnosis and treatment[J]. Cancers (Basel), 2013, 5(1):48-63. DOI:10.3390/cancers5010048. [40] Lee JW, Jo K, Cho A, et al. Relationship Between 18F-FDG Uptake on PET and Recurrence Patterns After Curative Surgical Resection in Patients with Advanced Gastric Cancer[J]. J Nucl Med, 2015, 56(10):1494-1500. DOI:10.2967/jnumed.115.160580. [41] Sun X, Wang J, Liu J, et al. Albumin concentrations plus neutrophil lymphocyte ratios for predicting overall survival after curative resection for gastric cancer[J/OL]. Onco Targets Ther, 2016, 9: 4661-4669[2018-01-07]. https://www.ncbi.nlm.nih/gov/pmc/articles/PMC4973773. DOI: 10.2147/OTT.S108631. [42] Grabinska K, Pelak M, Wydmanski J, et al. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer[J]. World J Gastroenterol, 2015, 21(19):5901-5909. DOI:10.3748/wjg.v21.i19.5901. [43] Ock CY, Kim TY, Lee KH, et al. Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implications[J]. Gastric Cancer, 2016, 19(2):421-430. DOI:10.1007/s10120-015-0504-1. [44] Wu Z, Zhao J, Gao P, et al. Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer:a meta-analysis[J]. BMC Cancer, 2017, 17(1):275. DOI:10.1186/s12885-017-3271-z. [45] Park JS, Lee N, Beom SH, et al. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status[J]. Gastric Cancer, 2018, 21(2):213-224. DOI:10.1007/s10120-017-0739-0. [46] Coupe NA, Karikios D, Chong S, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer[J]. Ann Nucl Med, 2014, 28(2):128-135. DOI:10.1007/s12149-013-0791-8. [47] Song BI, Kim HW, Won KS, et al. Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer[J/OL]. Medicine (Baltimore), 2015, 94(26): e1037[2018-01-07]. https://www.ncbi.nlm.nih.gov/pubmed/26131811. DOI: 0.1097/MD.0000000000001037.
计量
- 文章访问数: 4337
- HTML全文浏览量: 3504
- PDF下载量: 13